16 September 2026 editorial review · Trial
ADJUST-T1D: semaglutide with AID in adults with obesity: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: New historical RCT record from primary publication and posted results:72 randomized differs registry header 115;36% versus 0% composite, 26 weeks, two severe hypoglycemic events in each group and no DKA. Obesity and AID criteria explicit.
Registry: NCT05537233; COMPLETED; updated 2025-09-03; enrollment 115 (ACTUAL); results posted.
Endpoint comparison: Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group (26 weeks).
Sources for this record: ADJUnct Semaglutide Treatment in Type 1 Diabetes (NCT05537233) (registry); Semaglutide in Adults with Type 1 Diabetes and Obesity (peer-reviewed).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.